New Data from University of Iowa Hospitals and Clinic Illuminate Findings in Bladder Cancer (Prognostic Role of the Neutrophil/lymphocyte Ratio In High-risk Bcg-naive Non-muscle-invasive Bladder Cancer Treated With Intravesical...).

A recent study conducted at the University of Iowa Hospitals and Clinic investigated the role of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in predicting the response to sequential intravesical therapy for high-risk non-muscle-invasive bladder cancer (NMIBC). The study analyzed data from 115 patients who received gemcitabine and docetaxel therapy for NMIBC. The results showed that NLR was associated with recurrence-free survival (RFS), indicating its potential as a predictive marker for RFS in high-risk BCG-naive patients. However, further prospective trials are needed to validate these findings. [Extracted from the article]